RT Journal Article
SR Electronic
T1 Immune response after SARS-CoV-2 infection with residual post COVID symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.10.22280762
DO 10.1101/2022.10.10.22280762
A1 Pongkunakorn, Tanyaporn
A1 Manosan, Thamonwan
A1 Surawit, Apinya
A1 Ophakas, Suphawan
A1 Mongkolsucharitkul, Pichanun
A1 Pumiem, Sureeporn
A1 Suta, Sophida
A1 Pinsawas, Bonggochpass
A1 Sookrung, Nitat
A1 Saelim, Nawannaporn
A1 Mahasongkram, Kodchakorn
A1 Prangtaworn, Pannathee
A1 Tungtrongchitr, Anchalee
A1 Tangjittipokin, Watip
A1 Boonnak, Kobporn
A1 Narkdontri, Tassanee
A1 Teerawattanapong, Nipaporn
A1 Jongkaewwattana, Anan
A1 Mayurasakorn, Korapat
YR 2022
UL http://medrxiv.org/content/early/2022/10/10/2022.10.10.22280762.abstract
AB BACKGROUND In a number of patients, post-acute COVID syndrome develops after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Long COVID [LC]). Here, we examined the immune responses and clinical characteristics of individuals with LC compared to age- and gender-matched healthy recovered COVID individuals (HC) during the Omicron pandemic. Immune responses following BNT162b2 (Pfizer) booster are also determined.METHODS This retrospective cohort study included 292 patients (LC, 158; HC, 134) confirmed to have SARS-CoV-2 infection from January to August 2022. We determined anti-SARS-CoV-2 receptor-binding domain immunoglobulin G (anti-RBD IgG), surrogate virus neutralization test (sVNT), T-cell subsets, and neutralization of wild-type, BA.1 and BA.5. A subset of patients was voluntarily recruited for booster vaccination with BNT162b2 vaccine and immunogenicity was assessed 4weeks after vaccination.RESULTS Cycle thresholds were higher in the HC group than in the LC group (20.7 vs. 19.7; P<0.039). Anti-RBD IgG was higher at ≤56 days after COVID-19 onset (PC) in 3-dose vaccines compared with 2-dose vaccines in the LC group (P=0.02) and after 57-84 days PC in 3-dose vaccines in the HC group (P<0.001). The sVNT in LC was significantly high against Wuhan and sVNT was 30% lower against the Omicron than the Wuhan. sVNT was relatively sustained in 3-dose vaccines than ≤ 2-dose vaccines. sVNT in the HC group reached its peak at 57-84 days PC as compared with the LC group.CONCLUSIONS These findings imply that LC produced increased neutralizing antibody responses than those with HC. During the Omicron pandemic, immunity after LC has still waned; therefore, a booster vaccine may be needed after 2-3 months from last infection. (ClinicalTrials.gov number, NCT05484700)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05484700Funding StatementThis study was funded by the Faculty of Medicine, Siriraj Hospital, Mahidol University (grant number R016534004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB), Faculty of Medicine Siriraj Hospital, Mahidol University gave ethical approval for this work (COA no. Si 1036/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors